TT 103MH - Thrombotargets Corp

Biotecnología
Vein thrombosis
Trombosis treatment
Hemophilia treatment
Deep vein thrombosis symptoms
Superficial thrombosis

[ Cerrar ]

Discovery & Pipeline

Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays capable to quantify simultaneously clot formation and clot lysis (HemostaScreen), total antioxidant capacity (OxidantScreen) and low-density lipoprotein modification (AtheroScreen). With these proven proprietary new HTS Platforms (), Thrombotargets is creating a continuously novel and promising pipeline of drug candidates.

TT-103MH

TT-103MH FOR THE FIRST TIME, HAS BEEN ABLE TO STOP LETHAL HEMORRHAGE AVOIDING DEATH IN FACTOR VIII-DEFICIENT HEMOPHILIA A MICE.

Our biotech company is developing the first antihemorrhagic drug useful for treating topically all kinds of bleeding (healthy subject to any coagulation disease patient).

Surprisingly there are no drugs available today useful for the topical treatment of healthy subjects in the case of a simple episode of epistaxis or gingival bleeding after brushing one's teeth or simply due to an everyday wound caused by shaving, due to the punctured vein in a blood extraction, or due to the wound from an accidental fall in the street.

Contact

www.Thrombotargets.com
General: info@thrombotargets.com

Search keys: TT 103MH

Thrombotargets is developing TT- 103MH, a novel and significantly radical approach for the treatment of bleeding disorders. Using a topical formulation TT-103MH, will be effective in treating:

• Healthy subjects
• Haemophilic patients
• Inherited and acquired coagulation and platelet disorders
• Haemorrhages induced by anticoagulant and antiplatelet drugs.